CN110354152A - A kind of probiotic composition for reducing blood lipid - Google Patents
A kind of probiotic composition for reducing blood lipid Download PDFInfo
- Publication number
- CN110354152A CN110354152A CN201910765856.0A CN201910765856A CN110354152A CN 110354152 A CN110354152 A CN 110354152A CN 201910765856 A CN201910765856 A CN 201910765856A CN 110354152 A CN110354152 A CN 110354152A
- Authority
- CN
- China
- Prior art keywords
- parts
- dry powder
- powder
- polypeptide
- probiotic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of probiotic compositions for reducing blood lipid, including freeze-dried vaccine powder, polysaccharide, polyphenol and polypeptide, the freeze-dried vaccine powder includes lactobacillus acidophilus dry powder, Lactobacillus salivarius dry powder, S. cervisiae dry powder and bafillus natto dry powder, the polysaccharide includes pholiota nameko polysaccharide and/or sea grass polysaccharide, the polyphenol includes one or more of black tea polyphenols, raspberry polyphenol and pomegranate peel polyphenol, and the polypeptide includes one or more of soya-bean polypeptides, oat polypeptide and pawpaw polypeptide.
Description
Technical field
The present invention relates to probiotic composition more particularly to a kind of probiotic compositions for reducing blood lipid.
Background technique
Blood lipid is neutral fat (triglycerides and cholesterol) and lipoid (phosphatide, rouge, sterol, steroids) in blood plasma
General name is widely present in human body.There are many very important functions for blood lipid, but no more than certain range.If blood
Rouge is excessive, will lead to various diseases.
Currently, the control high to blood lipid is mainly based on drug.Probiotics can also improve the stomach strain of human body
Digestion power, improves digestive system to the capacity of decomposition of fatty cholesterol, can reducing blood lipid, realization treats hyperlipidemia
Effect therefore develop a kind of probiotic composition for capableing of reducing blood lipid, it is very necessary to improve patient's compliance.
Summary of the invention
In order to solve the above technical problems, the object of the present invention is to provide a kind of probiotic composition for reducing blood lipid, this
The probiotic composition of invention has hypolipemic function.
A kind of probiotic composition for reducing blood lipid of the invention, including freeze-dried vaccine powder, polysaccharide, polyphenol and polypeptide, institute
Stating freeze-dried vaccine powder includes that lactobacillus acidophilus dry powder, Lactobacillus salivarius dry powder, S. cervisiae dry powder and bafillus natto are dry
Powder, the polysaccharide include pholiota nameko polysaccharide and/or sea grass polysaccharide, and the polyphenol includes black tea polyphenols, raspberry polyphenol and granatum
One or more of polyphenol, the polypeptide include one or more of soya-bean polypeptides, oat polypeptide and pawpaw polypeptide.
Further, include the component of following weight for the probiotic composition of reducing blood lipid:
10-30 parts of lactobacillus acidophilus dry powder, 5-15 parts of Lactobacillus salivarius dry powder, 1-5 parts of S. cervisiae dry powder, natto bud
10-30 parts of spore bacillus dry powder, 5-15 parts of polysaccharide, 5-10 parts of polyphenol, 5-10 parts of polypeptide.
Further, include the component of following weight for the probiotic composition of reducing blood lipid:
12-18 parts of lactobacillus acidophilus dry powder, 8-12 parts of Lactobacillus salivarius dry powder, 3-5 parts of S. cervisiae dry powder, natto bud
15-25 parts of spore bacillus dry powder, 10-15 parts of polysaccharide, 5-8 parts of polyphenol, 5-8 parts of polypeptide.
Further, freeze-dried vaccine powder preparation method the following steps are included:
(1) lactobacillus acidophilus, Lactobacillus salivarius, S. cervisiae or bafillus natto are subjected to high density training respectively
It supports, obtains fermentation liquid, cell density is 5 × 108-10×108cfu/g；
(2) acquisition thallus is collected by centrifugation in above-mentioned fermentation liquid, and protective agent is added, freeze-dried vaccine powder is obtained after freeze-drying.
Further, in step (2), the protective agent includes skimmed milk powder, trehalose and maltodextrin.
Further, the mass ratio of the skimmed milk powder, trehalose and maltodextrin is 5-10:1-3:1-3.
Further, the technique of the freeze-drying is -40 DEG C to -50 DEG C dry 1-2h；Then at -20 DEG C to -30 DEG C
Dry 1-2h；Finally in 15-30 DEG C of dry 1-2h.
Further, the S. cervisiae dry powder derives from S. cervisiae SaccharomycesACCC20107.
Further, the viable count of freeze-dried vaccine powder is no less than 1.0 × 10 in probiotic composition10cfu/g。
It further, further include 1-5 parts of hawthorn powder for the probiotic composition of reducing blood lipid.
Further, lactobacillus acidophilus dry powder derives from lactobacillus acidophilus CGMCC No.1084, lactobacillus acidophilus CGMCC
One or more of No.12453 and lactobacillus acidophilus CCTCC NO:M2011035.
Further, Lactobacillus salivarius dry powder derives from Lactobacillus salivarius ZLS006, Lactobacillus salivarius CGMCCNo.12857
One or more of with Lactobacillus salivarius CGMCC No.6278.
Further, bafillus natto dry powder derives from bafillus natto CGMCC No.5769.
Further, for the preparation method of the probiotic composition of reducing blood lipid the following steps are included:
By lactobacillus acidophilus dry powder, Lactobacillus salivarius dry powder, S. cervisiae dry powder, bafillus natto dry powder, polysaccharide,
Polyphenol and polypeptide mix.
According to the above aspect of the present invention, the present invention has at least the following advantages:
Probiotic composition of the invention has blood fat reducing function, and preparation process is simple, can be by each component directly according to not
With obtained after proportion mixing.Probiotic composition active component content of the invention is high, and viable count is no less than 1.0 × 1010cfu/
g.Probiotic composition of the invention is in good taste, can be used as blood fat reducing food or health care product, and patient's compliance is high.
The above description is only an overview of the technical scheme of the present invention, in order to better understand the technical means of the present invention,
And can be implemented in accordance with the contents of the specification, below with presently preferred embodiments of the present invention and after cooperating drawings in detail to illustrate such as.
Detailed description of the invention
Fig. 1 is influence result of the probiotic composition for reducing blood lipid of the invention to mice serum cholesterol；
Fig. 2 is influence result of the probiotic composition for reducing blood lipid of the invention to mice serum bile acid；
Fig. 3 is influence result of the probiotic composition for reducing blood lipid of the invention to mice serum HDL-C level；
Fig. 4 is influence result of the probiotic composition for reducing blood lipid of the invention to mice serum LDL-C level.
Specific embodiment
With reference to embodiment, the embodiment of the present invention is furthur described in detail.Following embodiment is used for
Illustrate the present invention, but is not intended to limit the scope of the invention.
Embodiment 1
The preparation of freeze-dried vaccine powder: the preservation strain of acquisition being activated, is inoculated into culture medium, and cell density is 5 × 108-
10× 108After cfu/g, Anaerobic culturel 18h, fermentation liquid is obtained；Thalline were collected by centrifugation, and protective agent is added, and vacuum freeze drying obtains
Lactobacillus acidophilus dry powder, Lactobacillus salivarius dry powder, S. cervisiae dry powder or bafillus natto dry powder.Vacuum freeze drying
Technique is as follows: -40 DEG C of dry 2h；Then in -20 DEG C of dry 2h；Finally in 20 DEG C of dry 2h.
Wherein, preservation strain is S. cervisiae SaccharomycesACCC20107, lactobacillus acidophilus CGMCC
No.1084, Lactobacillus salivarius CGMCC No.12857 or bafillus natto CGMCC No.5769.
Protective agent is grouped as by each group of following mass fraction: skimmed milk powder 10%, trehalose 1%, maltodextrin 2%,
Surplus is water.
Embodiment 2
A kind of probiotic composition for reducing blood lipid, the component including following weight:
10 parts of lactobacillus acidophilus dry powder, 5 parts of Lactobacillus salivarius dry powder, 1 part of S. cervisiae dry powder, bafillus natto is dry
10 parts of powder, 5 parts of polysaccharide, 5 parts of polyphenol, 5 parts of polypeptide.
Wherein, polysaccharide is made of the pholiota nameko polysaccharide and sea grass polysaccharide of equal mass ratioes.Polyphenol is more by the black tea that mass ratio is 1:2
Phenol and raspberry polyphenol composition.Polypeptide is made of soya-bean polypeptides, oat polypeptide and the pawpaw polypeptide of equal mass ratioes.
The preparation method of probiotic composition for reducing blood lipid the following steps are included:
By lactobacillus acidophilus dry powder, Lactobacillus salivarius dry powder, S. cervisiae dry powder, bafillus natto dry powder, polysaccharide,
After polyphenol and polypeptide mix, preparation method and phase herein in following embodiment for the probiotic composition of reducing blood lipid
Together.
Embodiment 3
A kind of probiotic composition for reducing blood lipid, the component including following weight:
30 parts of lactobacillus acidophilus dry powder, 15 parts of Lactobacillus salivarius dry powder, 5 parts of S. cervisiae dry powder, bafillus natto
30 parts of dry powder, 15 parts of polysaccharide, 10 parts of polyphenol, 10 parts of polypeptide.
Wherein, polysaccharide is made of the pholiota nameko polysaccharide and sea grass polysaccharide of equal mass ratioes.Polyphenol by equal mass ratioes black tea polyphenols
It is formed with pomegranate peel polyphenol.Polypeptide is made of soya-bean polypeptides, oat polypeptide and the pawpaw polypeptide of equal mass ratioes.
Embodiment 4
A kind of probiotic composition for reducing blood lipid, the component including following weight:
18 parts of lactobacillus acidophilus dry powder, 11 parts of Lactobacillus salivarius dry powder, 3 parts of S. cervisiae dry powder, bafillus natto
14 parts of dry powder, 11 parts of polysaccharide, 8 parts of polyphenol, 7 parts of polypeptide.
Wherein, polysaccharide is made of the pholiota nameko polysaccharide and sea grass polysaccharide of equal mass ratioes.Polyphenol by equal mass ratioes black tea polyphenols,
Raspberry polyphenol and pomegranate peel polyphenol composition.Polypeptide is made of soya-bean polypeptides, oat polypeptide and the pawpaw polypeptide of equal mass ratioes.
Embodiment 5
A kind of probiotic composition for reducing blood lipid, the component including following weight:
12 parts of lactobacillus acidophilus dry powder, 8 parts of Lactobacillus salivarius dry powder, 5 parts of S. cervisiae dry powder, bafillus natto is dry
25 parts of powder, 13 parts of polysaccharide, 6 parts of polyphenol, 8 parts of polypeptide.
Wherein, polysaccharide is made of the pholiota nameko polysaccharide and sea grass polysaccharide of equal mass ratioes.Polyphenol by equal mass ratioes black tea polyphenols,
Raspberry polyphenol and pomegranate peel polyphenol composition.Polypeptide is made of soya-bean polypeptides, oat polypeptide and the pawpaw polypeptide of equal mass ratioes.
Embodiment 6
A kind of probiotic composition for reducing blood lipid, the component including following weight:
12 parts of lactobacillus acidophilus dry powder, 8 parts of Lactobacillus salivarius dry powder, 5 parts of S. cervisiae dry powder, bafillus natto is dry
25 parts of powder, 13 parts of polysaccharide, 6 parts of polyphenol, 8 parts of polypeptide, 2 parts of hawthorn powder.
Wherein, polysaccharide is made of the pholiota nameko polysaccharide and sea grass polysaccharide of equal mass ratioes.Polyphenol by equal mass ratioes black tea polyphenols,
Raspberry polyphenol and pomegranate peel polyphenol composition.Polypeptide is made of soya-bean polypeptides, oat polypeptide and the pawpaw polypeptide of equal mass ratioes.
Embodiment 7
The acute toxicity test of probiotic composition for reducing blood lipid
3 week old health hero, female C57BL6 mouse each 10 are taken, at 24 hours with 50mg probiotic composition/(kg/d)
Stomach-filling is observed 14, and record mouse weight, food ration and death state, blank group do not feed probiotic composition.The present embodiment
Probiotic composition used is the probiotic composition in embodiment 6.
As a result as shown in Table 1 and Table 2, feeding dietary supplements does not cause any negative effect to mouse, and mouse normally gives birth to
Long, the no phenomena of mortality generate, and without any pathological symptom.
Influence of the 1 feeding probiotic composition of table to mouse weight (g)
Influence of the 2 feeding probiotic composition of table to mouse food ration
Embodiment 8
Probiotic composition for reducing blood lipid is to the lipid of mouse
(1) it models: 50 female C57BL6 mouse being raised two weeks, are randomly divided into blank group (6) and model after two weeks
Group (6), all mouse carry out tail portion blood sampling.Blank group feeds normal diet, and model group is high lipid food.Mouse is recorded weekly
Weight, after feeding 4 weeks, tail portion blood sampling.
(2) after modeling successfully, blank group continues to feed normal diet, and model components are two groups, and one group is continued to feed high lipid food
(high in fat group), one group feed high lipid food while and to model group at 24 hours with 50mg probiotic composition/(kg/d) stomach-filling
(experimental group), in addition, the physiological saline isometric to blank group and high in fat group of stomach-filling.It carries out 4 weeks, tail portion blood sampling.The present embodiment
Probiotic composition used is the probiotic composition in embodiment 6.
By the blood of acquisition in 37 DEG C of placement 30min, 4 DEG C of centrifugations (15min, 2000rpm) isolate serum.Using examination
It is horizontal that agent box measures TC, TG, HDL-C, LDL-C in serum.As a result as shown in Figs 1-4.The result shows that modeling successfully, and blank
Content is in same level, no marked difference to group mouse in TC, TG, HDL-C, LDL-C serum before and after the experiment.Continuous gavage 4
Zhou Hou, TC, TG and LDL-C are significantly reduced in the mice serum of stomach-filling probiotic composition of the invention (experimental group), HDL-C
It is significant to increase, show that the lipid-lowering effect of probiotic composition of the invention is significant.
The above is only a preferred embodiment of the present invention, it is not intended to restrict the invention, it is noted that for this skill
For the those of ordinary skill in art field, without departing from the technical principles of the invention, can also make it is several improvement and
Modification, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (10)
1. a kind of probiotic composition for reducing blood lipid, it is characterised in that: including freeze-dried vaccine powder, polysaccharide, polyphenol and polypeptide, institute
Stating freeze-dried vaccine powder includes lactobacillus acidophilus dry powder, Lactobacillus salivarius dry powder, S. cervisiae dry powder and bafillus natto dry powder,
The polysaccharide includes pholiota nameko polysaccharide and/or sea grass polysaccharide, and the polyphenol includes black tea polyphenols, raspberry polyphenol and pomegranate peel polyphenol
One or more of, the polypeptide includes one or more of soya-bean polypeptides, oat polypeptide and pawpaw polypeptide.
2. the probiotic composition according to claim 1 for reducing blood lipid, which is characterized in that match including following parts by weight
The component of ratio:
10-30 parts of lactobacillus acidophilus dry powder, 5-15 parts of Lactobacillus salivarius dry powder, 1-5 parts of S. cervisiae dry powder, natto gemma bar
10-30 parts of bacterium dry powder, 5-15 parts of polysaccharide, 5-10 parts of polyphenol, 5-10 parts of polypeptide.
3. the probiotic composition according to claim 1 for reducing blood lipid, which is characterized in that match including following parts by weight
The component of ratio:
12-18 parts of lactobacillus acidophilus dry powder, 8-12 parts of Lactobacillus salivarius dry powder, 3-5 parts of S. cervisiae dry powder, natto gemma bar
15-25 parts of bacterium dry powder, 10-15 parts of polysaccharide, 5-8 parts of polyphenol, 5-8 parts of polypeptide.
4. the probiotic composition according to claim 1 for reducing blood lipid, which is characterized in that the system of the freeze-dried vaccine powder
Preparation Method the following steps are included:
(1) lactobacillus acidophilus, Lactobacillus salivarius, S. cervisiae or bafillus natto are subjected to High Density Cultivation respectively, obtained
To fermentation liquid, cell density is 5 × 108-10×108cfu/g；
(2) acquisition thallus is collected by centrifugation in above-mentioned fermentation liquid, and protective agent is added, freeze-dried vaccine powder is obtained after freeze-drying.
5. the preparation method according to claim 4, it is characterised in that: in step (2), the protective agent includes skimmed milk
Powder, trehalose and maltodextrin.
6. the preparation method according to claim 4, it is characterised in that: the skimmed milk powder, trehalose and maltodextrin
Mass ratio is 5-10:1-3:1-3.
7. the preparation method according to claim 4, it is characterised in that: the technique of the freeze-drying is -40 DEG C to -50 DEG C
Dry 1-2h；Then in -20 DEG C to -30 DEG C dry 1-2h；Finally in 15-30 DEG C of dry 1-2h.
8. the probiotic composition according to claim 1 for reducing blood lipid, which is characterized in that the S. cervisiae is dry
Powder derives from S. cervisiae SaccharomycesACCC20107.
9. the probiotic composition according to claim 1 for reducing blood lipid, which is characterized in that freeze in probiotic composition
The viable count of dry bacterium powder is no less than 1.0 × 1010cfu/g。
10. the probiotic composition according to claim 1 for reducing blood lipid, which is characterized in that further include hawthorn powder 1-5
Part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910765856.0A CN110354152A (en) | 2019-08-19 | 2019-08-19 | A kind of probiotic composition for reducing blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910765856.0A CN110354152A (en) | 2019-08-19 | 2019-08-19 | A kind of probiotic composition for reducing blood lipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110354152A true CN110354152A (en) | 2019-10-22 |
Family
ID=68224163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910765856.0A Withdrawn CN110354152A (en) | 2019-08-19 | 2019-08-19 | A kind of probiotic composition for reducing blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110354152A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111296828A (en) * | 2020-03-02 | 2020-06-19 | 中国农业科学院农产品加工研究所 | Preparation method of pomegranate peel enzyme powder capsule |
| CN114451558A (en) * | 2022-02-23 | 2022-05-10 | 广州市沐家健康产业有限公司 | Composite probiotic polypeptide tablet with weight-losing and lipid-lowering effects and preparation method and application thereof |
-
2019
- 2019-08-19 CN CN201910765856.0A patent/CN110354152A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111296828A (en) * | 2020-03-02 | 2020-06-19 | 中国农业科学院农产品加工研究所 | Preparation method of pomegranate peel enzyme powder capsule |
| CN114451558A (en) * | 2022-02-23 | 2022-05-10 | 广州市沐家健康产业有限公司 | Composite probiotic polypeptide tablet with weight-losing and lipid-lowering effects and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Probiotics in the dairy industry—Advances and opportunities | |
| JP6240386B2 (en) | Probiotic stabilization | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| EP2440073A1 (en) | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN103689595A (en) | Soft lactic acid bacteria capsule and preparation method thereof | |
| Putta et al. | Probiotics: supplements, food, pharmaceutical industry | |
| CN104415061B (en) | Edible composition and its production and use | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN110354152A (en) | A kind of probiotic composition for reducing blood lipid | |
| EP3091861A1 (en) | Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations | |
| CN111066888A (en) | Probiotic powder | |
| CN110075226A (en) | It is a kind of can be with the probiotic composition of reducing blood lipid | |
| Hamasalim | The impact of some widely probiotic (Iraqi probiotic) on health and performance | |
| Salvini et al. | Probiotics, prebiotics and child health: where are we going? | |
| CN106666738A (en) | Composition used for improving metabolic disorder status of human body and preparation method thereof | |
| CN106834186B (en) | Lactobacillus plantarum microecological preparation and preparation method and application thereof | |
| CN109527238A (en) | A kind of preparation method of the piglet feed of enteric solubility compound micro-ecological preparation | |
| Singh et al. | Nutraceuticals from bioengineered microorganisms | |
| JP5562986B2 (en) | Preventive or ameliorating agent for lifestyle-related diseases | |
| CN111888397B (en) | Lipid-lowering and weight-losing tea oil composition and application thereof, soft capsule and preparation method thereof | |
| JP5940475B2 (en) | Blood cortisol elevation inhibitor | |
| CN114304688B (en) | Zein coating agent, probiotics preparation coated by coating agent and preparation method thereof | |
| Yadav et al. | Probiotics and diabetes/obesity | |
| WO2011114322A1 (en) | Oil suspension-based molded food products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191022 |
|
| WW01 | Invention patent application withdrawn after publication |